Optimizing Contrast Dose and Scanning Parameters for Detection of Leptomeningeal Disease
Recruiting
N/A
Interventional Study
Leptomeningeal Disease
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Interventional
- Purpose
- Diagnostic
- Participants needed
- 40 (estimated)
- Sponsor
- M.D. Anderson Cancer Center · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
To learn if gadopiclenol (a contrast agent) used during MRI scanning can help in the detection of early LMD.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Patients with tissue confirmed solid malignancy and standard of care brain MRI with equivocal results for LMD (questionable or possible) and negative LP CSF sampling or patients with high risk clinical LMD and negative brain MR and LP CSF sampling. Initially, we will target so…
Contacts